Compare RMCO & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCO | NNVC |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 35.2M |
| IPO Year | 2021 | 2008 |
| Metric | RMCO | NNVC |
|---|---|---|
| Price | $2.66 | $1.02 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.2K | ★ 261.9K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,949,916.00 | N/A |
| Revenue This Year | $209.10 | N/A |
| Revenue Next Year | $133.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 513.30 | N/A |
| 52 Week Low | $1.74 | $0.85 |
| 52 Week High | $5.00 | $2.23 |
| Indicator | RMCO | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 19.26 |
| Support Level | $2.64 | $0.86 |
| Resistance Level | $3.04 | $1.07 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 20.72 | 2.26 |
Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.